Immune checkpoint inhibitors (ICIs) such as programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) blockade and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors are another representative breakthrough in cancer immunotherapy that has been successfully used in solid tumors (6). Here, CTLA4 is linked to cancer.